September 2003

The new United Kingdom-based firm has sites located in France, Spain, and Sweden, thanks to an acquisition of Synerlab Group and several Recipharm facilities in 2024.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.

Siemens said spending on AI software is predicted to double by the end of the 2020s, in a market increasingly driven by structural shifts that underscore a need for digital transformation.